1. Home
  2. TONX vs VTVT Comparison

TONX vs VTVT Comparison

Compare TONX & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TONX

TON Strategy Company

HOLD

Current Price

$3.98

Market Cap

134.0M

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$33.00

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TONX
VTVT
Founded
N/A
2015
Country
United States
United States
Employees
23
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.0M
148.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
TONX
VTVT
Price
$3.98
$33.00
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$53.00
AVG Volume (30 Days)
543.3K
29.7K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.26
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.75
$14.00
52 Week High
$8.23
$44.00

Technical Indicators

Market Signals
Indicator
TONX
VTVT
Relative Strength Index (RSI) 62.85 44.76
Support Level $2.96 $30.09
Resistance Level $4.31 $33.11
Average True Range (ATR) 0.48 2.60
MACD 0.03 -0.01
Stochastic Oscillator 85.50 32.56

Price Performance

Historical Comparison
TONX
VTVT

About TONX TON Strategy Company

TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: